Posted by Ritch on August 23, 2002, at 8:57:49
In reply to Re: Antipsychotic with lowest incidence of TD?, posted by cybercafe on August 23, 2002, at 1:13:11
> >They all just happen to be higher *potency* antipychotics (response/mg-dosage). The lower the potency, it seems, the less adverse effects-EPS-wise (despite a relatively higher dosage of the lower potency agent). This is highly personalized, so take it with a grain of salt.
>
> Okay here is where it gets tricky. Because of serotonin 5HT2A antagonism, atypicals have a lower incidence of EPS. They "hide" what is going on in the striatum (extrapyrimidal motor area). Normally I think a lower potency drug like seroquel/quetipane (dosage around 100 mg) would have lower eps than a higher potency drug like olanzapine/zyprexa, however! Zyprexa has a much higher potency for the 5HT2A receptor, which means it "hides" the EPS symptoms better. So... what i am wondering is... when you stop taking the drug where long term effects on the dopamine system would cause TD, do long term effects on the serotonin system still compensate?
> i can't answer this question, because i do not know the mechanism responsible for TD...
> that's why i can only go by anecdotal/experimental data
>
> thanks for your input dude ;)
Cyber,There is a lot of debate about whether the serotonergic activity of the newer meds has anything to do with less risk of TD or not. Cam W. mentioned that the relatively reversible binding qualities of the newer meds to DA receptors is more predictive of lesser risk of TD, and that's the only reason. He was supposed to post some info about it, but hasn't yet.
Mitch
poster:Ritch
thread:117396
URL: http://www.dr-bob.org/babble/20020821/msgs/117499.html